Teva Pharmaceutical Industries (TEVA) Liabilities and Shareholders Equity (2016 - 2025)
Teva Pharmaceutical Industries' Liabilities and Shareholders Equity history spans 17 years, with the latest figure at $40.7 billion for Q4 2025.
- For the quarter ending Q4 2025, Liabilities and Shareholders Equity rose 3.62% year-over-year to $40.7 billion, compared with a TTM value of $159.2 billion through Dec 2025, down 3.66%, and an annual FY2025 reading of $40.7 billion, up 3.62% over the prior year.
- Liabilities and Shareholders Equity for Q4 2025 was $40.7 billion at Teva Pharmaceutical Industries, up from $39.9 billion in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $49.2 billion in Q2 2021, with the low at $38.4 billion in Q1 2025.
- Average Liabilities and Shareholders Equity over 5 years is $43.6 billion, with a median of $43.3 billion recorded in 2023.
- Year-over-year, Liabilities and Shareholders Equity fell 11.43% in 2021 and then increased 3.62% in 2025.
- Tracing TEVA's Liabilities and Shareholders Equity over 5 years: stood at $47.7 billion in 2021, then dropped by 7.67% to $44.0 billion in 2022, then decreased by 1.21% to $43.5 billion in 2023, then decreased by 9.55% to $39.3 billion in 2024, then grew by 3.62% to $40.7 billion in 2025.
- Per Business Quant, the three most recent readings for TEVA's Liabilities and Shareholders Equity are $40.7 billion (Q4 2025), $39.9 billion (Q3 2025), and $40.1 billion (Q2 2025).